Alnylam Launches Phase II Trial of Second-Generation Amyloidosis Drug
June 07, 2012
Alnylam Launches Phase II Trial of Second-Generation Amyloidosis Drug
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Alnylam Loses Cubist as RSV Partner, Stays Focused on ATTR Programs
February 14, 2013 / Gene Silencing News - Alnylam Finds Partner for Cholesterol Program in The Medicines Company
February 7, 2013 / Gene Silencing News - IP Update: Recent Patents, Patent Applications Awarded to UNC, Alnylam, FSU, and More
February 7, 2013 / Gene Silencing News - Oligo Drugs Advance in the Clinic in 2012 as Delivery Hurdles are Addressed
January 3, 2013 / Gene Silencing News - Alnylam ATTR Program on Track as Company Explores Subcutaneous Delivery for Cholesterol Drug
November 8, 2012 / Gene Silencing News